BioCryst

YTD

ALL

Why Robinhood?

Robinhood gives you the tools you need to put your money in motion. You can buy or sell BioCryst and other ETFs, options, and stocks.

About BCRX

BioCryst Pharmaceuticals, Inc. is a biotechnology company. It engages in the provision of structure-guided drug design with the goal of developing oral small-molecule and protein therapeutics to target difficult-to-treat rare diseases.

CEO

Jon P. Stonehouse

CEOJon P. Stonehouse

Employees

580

Employees580

Headquarters

Durham, North Carolina

HeadquartersDurham, North Carolina

Founded

1986

Founded1986

Employees

580

Employees580

BCRX Key Statistics

Market cap

2.13B

Market cap2.13B

Price-Earnings ratio

-39.53

Price-Earnings ratio-39.53

Dividend yield

—

Dividend yield—

Average volume

9.74M

Average volume9.74M

High today

$10.41

High today$10.41

Low today

$9.82

Low today$9.82

Open price

$9.93

Open price$9.93

Volume

6.47M

Volume6.47M

52 Week high

$11.11

52 Week high$11.11

52 Week low

$5.92

52 Week low$5.92

BCRX News

TipRanks 2d

BioCryst’s Strategic Advancements and Market Potential: A Buy Rating by Serge Belanger

Needham analyst Serge Belanger has maintained their bullish stance on BCRX stock, giving a Buy rating on May 6. Protect Your Portfolio Against Market Uncertain...

Seeking Alpha 2d

BioCryst's Orladeyo up for FDA review in pediatric HAE patients

BioCryst Pharmaceuticals (NASDAQ:BCRX) said on Wednesday that the U.S. FDA will review the marketing application of Orladeyo in patients aged between 2 and 11 y...

Analyst ratings

92%

of 12 ratings

Buy

91.7%

Hold

8.3%

Sell

People also own

Based on the portfolios of people who own BCRX. This list is generated using Robinhood data, and it’s not a recommendation.